Cohort name

Leader

Total patients in database

Total patients in the biobank

New patients per year

Nature of the samples/data

Resources

TELARTA

A. Benetos

Participants: 5 other groups from Nancy (2) and Marseille (3)

74/340 (ongoing)

74

(human tissues)

340 (to be recruited during the period 07/2014- 12/2015

Links between arterial ageing and telomere length (TL), as expressed in different tissues, and TL dynamics, as expressed in the difference between TLs of muscle and leukocytes - Prospective study

ANR-Translational N°ID RCB: 2014-A00298-39: 2014- 2017

ADELAHYDE

A. Benetos

Participants: 3 other groups from Nancy (2) and Caen (1)

369

369

blood, DNA

Complete

Arterial stiffness and leukoaraiosis in the evolution of cognitive decline in the elderly, over a 7-year follow-up period. Longitudinal prospective study

PHRC 2010-A01399-30

4 publications

ERA

A. Benetos

Monocentric

660

660

Blood, DNA

Completed

Role of genetic and hemodynamic parameters in the development of arterial stiffness over a period of 15 years. Longitudinal prospective study

FRM DCV-2007-0409250

8 publications

ARTEOS

A. Benetos and G. Weryha

Monocentric CHU Nancy (Osteoporosis-Geriatrics)

310

310

Blood DNA

Completed

Relationships between arterio-sclerosis and osteoporosis. Cross-sectional prospective study

CPRC 2004 and PPF: 815PSVT- 2005

3 publications

TRANSARTE

L. Frimat and A. Benetos

Monocentric

CHU Nancy (Nephrology-Geriatrics)

100

Completed

Effects of renal transplantation versus dialysis on the evolution of arterial stiffness.

Longitudinal prospective case-control study

CPRC 2006 

1 publication

PARTAGE

A. Benetos

Multicentric: 5 French and 2 Italian Academic centers coordinating 72 Nursing Homes

1130

0

Completed

Individuals >80 years old living in nursing homes. Assess the arterial parameters in very elderly frail subjects. Data on morbidity and mortality over a follow-up period of 5 years.

Longitudinal prospective study

PHRC 2006-A00042-49 and INSERM 2011-ASE11067MSA

8 publications

STANISLAS Cohort

F. Zannad

4 295

4 295

2014: ongoing

Follow-up of the 4300 patients every five years

Initially healthy families ; Samples:

EDTA Plasma, Serum, Heparin Plasma, Citrate Plasma, Urine, PAXGEN RNA, PAXGEN DNA, Buffy Coat

Data: clinical, CV structure and function

CHU Nancy, PHRC, EU FP7

HOMAGE

F. Zannad

>45,000

30,000

completed

HF prone participants (international cohorts & RCTs) : plasma, serum, urine

EU FP7

BIOSTAT-HF

  1. Voors

2500

 

completed

HF patients at discharge after acutely decompensated HF

EU FP7

FIBROTARGETS

F. Zannad

34,000

Ongoing assessment

ongoing

HF prone participants and HF-PEF patients (international cohorts & RCTs) : plasma, serum, urine

EU FP7

MEDIA

F. Zannad

562/750 scheduled

562

Ongoing until 12/2015

DHF ; Samples: EDTA Plasma, Serum, Heparin Plasma, Citrate Plasma, Urine, PAXGEN RNA & DNA

EU FP7

REMI

N. Girerd

145

145

Study completed

Post MI : EDTA Plasma, Serum, PAXGEN DNA

PHRC

R2C2 1

R2C2 2

F. Zannad, P. Rossignol

200/89

R2C2 1 : 200.

R2C2 2 : 89

R2C2 1 : Study completed

R2C2 2 : Ongoing

Abdominal obesity ; Samples: Serum, EDTA Plasma, DNA

PHRC

EPICAL 2

N Thilly (PI),

N Agrinier (Co-PI)

2500

200

Recruitment completed

Acutely decompensated HF ; Sociodemographics, clinical, echocardiographic, biologic, mortality and readmissions

PHRC

EPHESUS

F. Zannad In collaboration with Pfizer

400

400

Study completed

HF post MI ; Samples: EDTA Plasma, Serum

Trial sponsored by Pfizer

ALCHEMIST

P. Rossignol

110/750

90

Study ongoing until June 2018

Hemodialysis Samples: EDTA Plasma, Serum, Blood for DNA extraction

PHRC

GREAT network

A. Mebazaa, Paris

30,000

3,000

700

Acutely decompensated HF Plasma

Inserm, APHP

FROG-ICU

A. Mebazaa, Paris

2,200

2,200

Inclusion completed

Acutely decompensated HF Plasma, urine

PHRC

FHU-CARTAGE © 2015 - BY MLCOM

Legal notices | Contact

We use cookies to improve our website. Cookies used for the essential operation of this site have already been set. For more information visit our Cookie policy. I accept cookies from this site.Agree